Scrip Watch

Alkem Laboratories Limited

Scrip Sanctuaries for protection from the wildlife in this jungle of Indian Equities

Alkem Laboratories Limited

Alkem Laboratories Limited

IPO Opens on Dec 8, 2015
IPO Closes on Dec 10, 2015
IPO Type 100% Book Built Issue
Equity Shares  Offered 12853442 Equity Shares
Face Value of Shares Rs 2 Per Equity Share
Price Band Rs 1020 – Rs 1050 Per Equity Share
Market Lot 14 Shares
Issue Size  Rs 1311.05 – 1349.61 Crs
Listing on BSE, NSE
Lead Managers Axis Capital Limited, Edelweiss Capital Limited ,  J.P. Morgan India Private Limited,  Nomura Financial Advisory And Securities (India) Pvt Ltd
Object of the issue To achieve the benefits of listing the Equity Shares on the Stock Exchanges
For the sale of 12,853,442 Equity Shares by the Selling Shareholders.

 

Recent Updates:

CCI imposes Rs 74 cr fine on Alkem Labs

IPO momentum: Dr Lal PathLabs, Alkem big hits in the grey market 

Overview

Alkem Labs is a pharmaceutical company which is involved in the development, manufacture and sale of pharmaceutical and neutraceutical products. It was incorporated in 1973 and is based in Maharashtra, India. The pharmaceutical major produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 other countries internationally, primarily the United States.

It has a diverse portfolio of over 736 brands in India. Company’s most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients.

The Company has 16 manufacturing facilities out of which 14 manufacturing facilities are based in India while two in the United States. Out of 14 Indian units two are R&D facilities whereas both the facilities in the US are R&D. The firm employs a total of 483 scientists in the R&D field. Five of its facilities are USFDA, TGA and UK-MHRA approved. Of the Indian manufacturing facilities, 12 are for manufacturing formulations and two for manufacturing APIs.

 

As of FY 15, Alkem Labs stands as fifth largest pharmaceutical company in India in terms of domestic sales. In the United States, company has filed 66 abbreviated new drug applications.

It has invested Rs 150-200 Crs for expansion in US facility and in the domestic market. About 75% of its revenue comes from domestic market and remaining 25% from international business with a about 3.6% market share. It currently has a cash of Rs 1500 Crs in its books

Promoters
Mr. Samprada Singh
Mr. Basudeo N. Singh

Consolidated Financial Trend ~ Amt in Rs Crs

Particulars 2015 2014 2013 2012 2011
Total Sales 3964 3291 2662 2161 1804
PAT 461 435 384 406 396
EPS (Rs) 39 36 32 34 33
Equity Cap 23.9 11.96 11.96 11.96 11.96
Net Worth 2999 2721 2308 1869 1465
BV (Rs) 251 228 193 156 123
Long Term Debt 33 232 256 309 246

 

 

 

 

Excerpts from Gaurav’s Blog

  Rest in Peace now Gerela Saab  ! Mr S T Gerela ex GM of BSE passed away peacefully this morning We had not met in years but he always remained at the top of my mind when it came to testimonials for this is what he had said to me over a decade ago,when […] [...]

Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! Promoter Group of  Vedanta Ltd has proposed a voluntary de-listing at an indicative offer price of Rs 87.50~are the over 7.3 lakh minority shareholders from Alibag !? …apologies to the people of Alibag Some would term this as De-listing Duplicity ~ but I would […] [...]

This is a Riskless Reliance Industries Rights Investment Strategy for those over 2.3 Million Shareholders already holding RIL shares. It is not a recommendation to buy RIL cum rights  It’s a no brainer yet I’m just penning a brief note because some have told me they hold Reliance but are skipping the Rights ! Don’t […] [...]

 Wealth is negotiable, Health is not Your Personal Well Being is more important that the Stock Market Well Being ~ Always & more so in this unfathomable ongoing Covid-19 Reality Above’s a three minute reach out by me last night to all connected with me to reinforce this .It’s also posted on Facebook , […] [...]

Yes Bank ~ Has the RBI & MOF lost it !? SEBI really is a bystander here Controversial Lock In Clause 3 Sub Clause 8 (a) in the Scheme of Reconstruction  No wonder the Finance Minister Mrs Nirmala Sitharaman, while highlighting only selected points, even when asked for details of the Scheme,did not want to […] [...]